John Investments
Watchlist

Research Report

Website ↗
HHinge Health logo

Hinge Health, Inc. · Digital Health · United States · NYSE:HNGE

IPOPublic
Latest valuation
$0
May 22, 2025
Revenue
$0
breakeven
Total raised
$0
0 rounds
99
IPO readiness
Q2 2025

Overview

Hinge Health delivers a digital musculoskeletal care platform combining exercise therapy, wearable sensors and clinicians, sold to employers and health plans.

Hinge Health operates in Digital Health, headquartered in United States, and is currently classified as ipo. It is a maturing business founded in 2014 and today runs a large-scale operation of roughly 1.60K people. Private market participants most recently referenced the business at approximately $3.90B. Its product surface spans MSK Program, Enso Device, TrueMotion. The company monetizes primarily through per-member contracts with employers and health plans.

MSK ProgramEnso DeviceTrueMotion

Company facts

Founded
2014
Headquarters
San Francisco, USA
Employees
1,600
CEO
Daniel Perez
Model
per-member contracts with employers and health plans

Investor network

The institutions backing the company, by conviction.

Tiger GlobalInsight PartnersCoatueBessemer Venture PartnersICONIQHH

Path to public markets

IPO readiness is assessed at roughly 99% on our internal scale, reflecting scale, financial maturity and observed pre-listing signals. If current momentum holds, a listing could plausibly land around 2025 on the NYSE. Stronger, audited financial disclosure would be the clearest step toward genuine IPO readiness.

  1. s1 filingApr 21, 2025
  2. pricedMay 21, 2025
    Priced at $32 · raised $437M · Morgan Stanley, BofA Securities, Goldman Sachs
  3. listedMay 22, 2025

IPO parameters

Readiness
public
Filing status
effective
Exchange
NYSE
Proposed ticker
HNGE
Expected
Q2 2025
Lock-up
180 days

The investment case

The core thesis on Hinge Health rests on its position within Digital Health, validated by backing from Tiger Global, Coatue, Insight Partners, having raised on the order of $1B to date. Reported revenue near $390M suggests the model has moved beyond early product-market fit into durable commercial traction.

Bull case

Bull case: Hinge Health compounds its lead in Digital Health, converts strong product engagement into expanding, high-margin revenue, and uses brand and balance-sheet strength to enter adjacent markets. A well-received public listing would provide currency for acquisitions and a re-rating toward best-in-class multiples.

Bear case

Bear case: growth normalizes faster than expected, competition compresses margins, and a tighter funding environment forces dilutive raises or down-rounds. In that scenario, secondary prices drift below prior marks and any IPO is delayed until conditions improve.

Growth drivers

Growth is driven by demand within Digital Health, particularly across MSK Program, Enso Device, TrueMotion. Expansion levers include new product lines, geographic reach, and deeper monetization of the existing customer base. Recurring revenue characteristics, where present, improve predictability and support a premium valuation multiple.

Key risks

Key risks include competitive pressure from peers such as Sword Health, Omada Health, Teladoc. A reliance on external financing exposes the company to shifts in private-market sentiment and the cost of capital. Private valuations can also lag public re-ratings, so a future listing or secondary transaction could reprice the business in either direction. As with any private company, disclosure is limited and figures shown here should be treated as estimates pending primary filings.

Competitive landscape

Hinge Health competes against Sword Health, Omada Health, Teladoc. Differentiation typically comes from product depth, distribution, switching costs, and the strength of its investor and talent base. The category is dynamic, and relative positioning can shift quickly as capital and attention rotate.

Filings & sources

FormTitleFiled
S-1Hinge Health S-1Apr 21, 2025

Data quality

Compiled from 3 sourced data points with an aggregate confidence of 75%. Public-company financials are pulled from SEC EDGAR; private valuations are the most recent publicly reported figures.

Last reviewed Jul 26, 2026. Verify against primary filings before relying on these figures.